August 20, 2025Open Access

Figure 3 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Longitudinal analysis shows improved rwPFS and rwOS for patients with high tumor fraction, suggesting a potential biomarker for therapy efficacy.

Improved rwPFS observed for MR with a HR of 0.24, indicating significant benefit compared to nMR.
Kaplan-Meier analysis demonstrated median rwOS of 7.166 months for MR, which is noteworthy among patients.
Analysis involved 521 patients across pan-solid tumors, assessing the role of ctDNA in clinical outcomes.
The findings may support ctDNA as a promising biomarker for predicting responses to immune checkpoint inhibitors.

Liang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Longitudinal analysis shows improved rwPFS and rwOS for patients with high tumor fraction, suggesting a potential biomarker for therapy efficacy.